Abstract: Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.

Abstract: Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.

Abstract: Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.

Abstract: The present invention provides a solid form and compositions thereof, which are useful as metal chelators and which exhibit desirable characteristics for the same.

Abstract: The present invention provides, among other things, effective oral formulations based on desazadesferrithiocin polyether (DADFT-PE) analogs, salts and polymorphs thereof, as well as their application for treatment of metal overload, in particular, iron overload, and associated diseases, disorders and conditions.

Abstract: Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogs, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.

Abstract: Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.

Abstract: Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.

Abstract: Disclosed herein are new compounds of desazadesferrothiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.

Abstract: Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.

Abstract: Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.

Abstract: Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.

Abstract: Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.

Abstract: Disclosed herein are new compounds of desazadesferrothiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.

Abstract: Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.

Abstract: A database is populated for further medical characterization through a world wide network of computers. The database is populated with a plurality of user health information from a plurality of users. The user health information includes genetic data and phenotypic data for a user. The database is populated at least in part through browsing activities of the plurality of users on the world wide network of computers.

Abstract: The present invention provides methods and materials to identify genetic abnormalities that predispose an individual to ion-channel diseases. The invention provides four polymorphic sites in the KCNQ1 gene that cause reduced conductance of the associated potassium ion channel current and a variant form of the KCNE1 gene which causes decreased conductance though the channel. The variant form of KCNE1 also acts synergistically with variants of KCNQ1 to cause further decreased conductance than either variant alone. The invention further provides polymorphisms in ion channel genes showing a higher frequency in populations afflicted with ion channel diseases or within control groups. The detection of these polymorphic sites that produce the potassium ion channel protein variants in either heterozygous or homozygous form in a subject indicates that the subject has, or is susceptible to, ion channel diseases such as congenital or acquired cardiac arrhythmia, LQT syndrome, SIDS, epilepsy, or hearing loss.

Abstract: A secured database is populated with genotypic and phenotypic data using a server coupled with a world wide network of computers. The server provides a web site configured to create trust of the web site by users. Users are invited to submit phenotypic data, and users are invited to submit a biological sample. The secured database is populated with received phenotypic data, and received biological samples are analyzed to obtain genetic data. The secured database is populated with the genetic data obtained from biological samples. Users that previously submitted phenotypic data are prompted to submit new phenotypic data, and the secured database is populated with the received prompted new phenotypic data. The secured database is prompted with received unprompted new phenotypic data.

Abstract: A method for aggregating persons with a select profile for further medical studies. The method includes browsing one or more selected electronic sites directed to medical information by a user of a selected profile at a client location, which is coupled to a worldwide area network of computers comprising an Internet. The method also includes profiling user (e.g., observed) for selected area of medicine through the browsing activities at a server location that is coupled to the worldwide area network of computers. A step of inquiring about specific information (e.g., form) from user at the client through one or more inquiries from the server is also included. The method further includes inputting information about the specific information from the client that is transferred to the server location; and delivering additional information on selected area of medicine from the server location to the client.

Abstract: The present invention provides a variety of methods for determining the identity of a nucleotide present at a variant site in a target nucleic acid. The methods involve conducting partial chain termination sequencing reactions of a target nucleic acid of interest conducted with the four deoxynucleotides but only one to three non-extendible nucleotides (i.e., analogs of dATP, dTTP, dGTP and dCTP that are non-extendible by a polymerase). The non-extendible nucleotide(s) utilized in the sequencing reactions are selected to be complementary to the bases potentially occupying the variant site of a target nucleic acid that serves as a template during sequencing. Analyses can also be performed in multiplex formats.